Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2015, Vol. 37 ›› Issue (1): 61-65.doi: 10.3881/j.issn.1000-503X.2015.01.011

• Orginal Article • Previous Articles     Next Articles

Changes in Thyroglobulin Antibodies after Treatment of Differentiated Thyroid Cancer and Its Influencing Factors

Hui CONG1, Jun LIANG2, Fang LI1, Wen-sheng QIU2(), Yan-song LIN1()   

  1. 1Department of Nuclear Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
    2Department of Oncology,the Affiliated Hospital of Qingdao University,Qingdao,Shandong 266003,China.
  • Received:2014-08-13 Online:2015-02-28 Published:2015-02-12

Abstract: ObjectiveTo investigate the changes in thyroglobulin antibodies(TgAb)and its influencing factors in differentiated thyroid cancer(DTC)patients with positive TgAb(>115 U/ml)after total thyroidectomy and radioiodine(131I)therapy. MethodsWe collected the clinical data of 118 DTC patients with positive TgAb and analyzed their TgAb levels before surgery,before 131I therapy,and after 131I therapy with a median follow-up of 2.3 months and 5.2 months. Multiple linear regression(MLR)was applied to analyze the time of TgAb concentration decreased by more than 50%(T50)and its influencing factors. ResultsCompared with the previous TgAb levels,TgAb decreased significantly 2.3 months and 5.2 months after surgery or after 131I therapy,respectively(both P=0.000). The proportions of patients with TgAb decreased by more than 50% in each stage were 28.6%,33.3%,and 37.2%,respectively. The negative conversion ratios were 23.4%,48.9%,and 62.8%,respectively. MLR showed that only the interval between surgery and 131I therapy was correlated with T50(B=1.125,P=0.000). ConclusionsThe TgAb levels in DTC patients remarkably decrease after surgery and after 131I therapy. The interval between surgery and 131I therapy remarkably influences the lowering speed of TgAb levels. Prompt application of 131I therapy after surgery helps to lower TgAb levels.

Key words: differentiated thyroid cancer, thyroglobulin antibodies, 131I therapy, surgical therapy

CLC Number: